Impact on the timing of metamizol administration on the platelet aggregation-inhibiting effect of acetylsalicylic acid in patients after aortic coronary bypass surgery
Not Applicable
- Conditions
- I25.1I25.13Atherosclerotic heart disease
- Registration Number
- DRKS00028161
- Lead Sponsor
- Klinik für Anästhesiologie, Universitätsklinikum Regensburg
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 98
Inclusion Criteria
Adult patients undergoing aortocoronary bypass surgery who give their written consent to the study
Exclusion Criteria
- Minority
- Pregnancy
- Hypersensitivity to metamizole
- Hypersensitivity to acetylsalicylic acid
- Hypersensitivity to other ingredients of the medication used
- Chronic pain treated with an NSAID
- Hematopoietic disorders
- above-average tendency to bleed
- genetically determined glucose-6-phosphate dehydrogenase deficiency
- Acute intermittent hepatic porphyria
- Hypotension with unstable circulatory situation
- acute gastrointestinal ulcers
- Liver failure
- Kidney failure
- severe uncontrolled heart failure
- Taking methotrexate at a dose of 15 mg or more per week
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Platelet function test from citrate blood recorded using Multiplate and thrombelastography (TEG 6S) at 6 defined time points: preoperative, 2 hours after surgery, on 1st + 2nd + 3rd + 7th postoperative day
- Secondary Outcome Measures
Name Time Method postoperative analgesia, pain monitoring, cardiac enzymes, critical events